SCHEMBL25554158

SCHEMBL25554158

Cc1ccc(C2CC(=O)C2)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM7 Q14831 6/20 0.49
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
PBRM1 Q86U86 1/20 0.38
ALDH1A1 P00352 2/20 0.37
ALDH2 P05091 1/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
BRCA1 P38398 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.36
MGLL Q99685 2/20 0.36
AADAT Q8N5Z0 2/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13454023 0.92 GRM7 (0.47) GRM7CHRNB2CHRNA4ACHEGAA
SCHEMBL20836353 0.85 GRM7 (0.48) GRM7CHRNB2CHRNA4PBRM1ALDH1A1
SCHEMBL31483678 0.85 GRM7 (0.48) GRM7CHRNB2CHRNA4PBRM1ALDH1A1
SCHEMBL23625888 0.81 TP53 (0.49) GRM7CHRNB2CHRNA4ACHEPBRM1
SCHEMBL14370207 0.81 GRM7 (0.44) GRM7CHRNB2CHRNA4GAAMAPT
SCHEMBL25376661 0.80 GRM7 (0.42) GRM7GAAMAPTLMNAMGLL
SCHEMBL15567031 0.79 CHRNB2 (0.44) GRM7CHRNB2CHRNA4ACHEALDH1A1
SCHEMBL13263971 0.78 GRM7 (0.42) GRM7MAPTALDH1A1LMNAMGLL
SCHEMBL25211397 0.78 CHRNB2 (0.44) CHRNB2CHRNA4MAPTAADAT
SCHEMBL25374556 0.78 GRM7 (0.43) GRM7GAAMAPTLMNAMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 GRM7 814/4885CHRNB2 1729/4885CHRNA4 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.